美國抗毒素市場規模、佔有率和趨勢分析報告：按類型、作用機制、最終用途和細分市場預測，2025 年至 2030 年

美國抗蛇毒血清市場概況

預計 2024 年美國抗蛇毒血清市場規模為 4.245 億美元，到 2030 年將達到 6.7 億美元，2025 年至 2030 年期間的複合年成長率為 8.0%。由於毒咬和毒蜇事件（尤其是蛇和昆蟲的毒咬和蜇刺事件）的發生率不斷上升，市場正在擴大。

都市化、森林砍伐和氣候變遷正在影響這些動物的棲息地，並加劇了有毒物種與人類之間的互動。這些趨勢推動了美國毒液中毒治療產業的發展，增加了對有效毒液中毒治療的需求，以減少毒液中毒造成的死亡和長期健康併發症。

生物技術的進步對市場成長貢獻巨大。單株抗體抗蛇毒藥物和重組DNA技術等進展，正在推動更有效、更安全的標靶治療療法的開發。這些技術進步正在改善治療效果，降低生產成本，使抗蛇毒血清更容易取得。製藥公司和研究機構（尤其是在美國）持續不斷的研發投入，正在推動創新，並促進針對特定蛇毒類型的先進抗蛇毒血清的推出。

美國市場受惠於其健全的醫療保健體系，能夠在緊急情況下快速獲得抗蛇毒治療。戶外休閒活動的日益普及以及市場向野生動物棲息地的擴張，增加了接觸有毒生物的可能性，從而推動了市場需求。此外，主要產業參與企業的參與以及政府對醫藥創新的持續支持，也增強了市場的成長前景。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國抗蛇毒血清市場變數、趨勢與範圍

• 市場體系展望
  • 母市場展望
  • 相關/附隨市場展望
• 市場動態
  • 市場促進因素分析
  • 市場限制因素分析
• 美國抗蛇毒血清市場分析工具
  • 產業分析—波特五力分析
  • PESTEL分析
• 美國抗毒素市場：管道分析

第4章：美國抗毒素市場類型、估價與趨勢分析

• 物種細分儀表板
• 美國抗蛇毒市場：物種變異分析
• 美國抗毒素市場規模及趨勢分析（按類型，2018-2030）
• 蛇
  • 普通眼鏡蛇
  • 普通板條箱
  • 拉塞爾·維珀
  • 其他
• 蠍
• 蜘蛛
• 其他

第5章：美國抗毒素市場類型、估價與趨勢分析

• 類型細分儀表板
• 美國抗毒素市場：類型變化分析
• 美國抗毒素市場規模及趨勢分析（2018-2030）
• 多效價
• 單一值

第6章：美國抗毒素市場的作用機制、估價與趨勢分析

• 作用機制細分儀表板
• 美國抗毒素市場：作用機制變異分析
• 美國抗毒素市場規模及趨勢分析（依作用機制，2018-2030）
• 細胞毒性
• 神經毒性
• 血液毒性
• 心臟毒性
• 肌肉毒性
• 其他

第7章：美國抗毒素市場最終用途、預測與趨勢分析

• 最終用途細分儀表板
• 美國抗毒素市場：最終用途差異分析
• 2018-2030年美國抗毒素市場規模及最終用途趨勢分析
• 醫院
• 診所
• 門診手術中心

第8章 競爭態勢

• 主要市場參與企業的近期趨勢和影響分析
• 公司/競爭對手分類
• 供應商格局
  • 2024年主要企業熱圖分析
• 公司簡介
  • Boehringer Ingelheim
  • CSL Limited
  • Merck & Co., Inc.
  • Pfizer, Inc.

U.S. Anti-Venom Market Summary

The U.S. anti-venom market size was estimated at USD 424.5 million in 2024 and is projected to reach USD 670.0 million by 2030, growing at a CAGR of 8.0% from 2025 to 2030. The market is expanding due to the rising incidence of venomous bites and stings, especially from snakes and insects.

Increased human interaction with venomous species is fueled by urbanization, deforestation, and climate change, which have impacted the habitats of these animals and brought them closer to populated areas. This trend has heightened the need for effective anti-venom treatments to reduce fatalities and long-term health complications associated with envenomation, driving the U.S. anti-venom industry.

Advancements in biotechnology significantly contribute to market growth. Innovations such as monoclonal antibody-based anti-venoms and recombinant DNA technologies have resulted in the development of more potent, safer, and targeted therapies. These improvements enhance treatment outcomes and help reduce production costs, making anti-venoms more accessible. The continuous research and development efforts by pharmaceutical companies and research institutions, particularly in the U.S., foster innovation and the introduction of advanced anti-venom products tailored to specific venom types.

The U.S. market benefits from a robust healthcare system that facilitates rapid access to anti-venom treatments in emergency settings. The prevalence of outdoor recreational activities and expanding urban development into wildlife habitats increases the likelihood of encounters with venomous species, thereby driving market demand. Moreover, the presence of key industry players and ongoing government support for pharmaceutical innovation strengthen the market's growth prospects.

U.S. Anti-Venom Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. anti-venom market report based on species, type, mode of action, and end use.

• Species Outlook (Revenue, USD Million, 2018 - 2030)
• Snake
  • Common Cobra
  • Common Krait
  • Russell Viper
  • Others
• Scorpion
• Spider
• Other
• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Polyvalent
• Monovalent
• Mode of Action Outlook (Revenue, USD Million, 2018 - 2030)
• Cytotoxic
• Neurotoxic
• Hemotoxic
• Cardiotoxic
• Myotoxic
• Others
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Clinics
• Ambulatory Surgical Centers

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Species
  • 1.2.2. Type
  • 1.2.3. Mode of action
  • 1.2.4. End use
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Species outlook
  • 2.2.2. Type outlook
  • 2.2.3. Mode of action outlook
  • 2.2.4. End use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Anti-Venom Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Anti-Venom Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. U.S. Anti-Venom Market: Pipeline Analysis

Chapter 4. U.S. Anti-Venom Market: Species Estimates & Trend Analysis

• 4.1. Species Segment Dashboard
• 4.2. U.S. Anti-Venom Market: Species Movement Analysis
• 4.3. U.S. Anti-Venom Market Size & Trend Analysis, by Species, 2018 to 2030 (USD Million)
• 4.4. Snake
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Common Cobra
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Common Krait
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Russell Viper
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Scorpion
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Spider
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Other
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Anti-Venom Market: Type Estimates & Trend Analysis

• 5.1. Type Segment Dashboard
• 5.2. U.S. Anti-Venom Market: Type Movement Analysis
• 5.3. U.S. Anti-Venom Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Polyvalent
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Monovalent
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Anti-Venom Market: Mode of Action Estimates & Trend Analysis

• 6.1. Mode of Action Segment Dashboard
• 6.2. U.S. Anti-Venom Market: Mode of Action Movement Analysis
• 6.3. U.S. Anti-Venom Market Size & Trend Analysis, by Mode of Action, 2018 to 2030 (USD Million)
• 6.4. Cytotoxic
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Neurotoxic
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Hemotoxic
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Cardiotoxic
  • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Myotoxic
  • 6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Others
  • 6.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Anti-Venom Market: End Use Estimates & Trend Analysis

• 7.1. End Use Segment Dashboard
• 7.2. U.S. Anti-Venom Market: End Use Movement Analysis
• 7.3. U.S. Anti-Venom Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Clinics
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Ambulatory Surgical Centers
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Boehringer Ingelheim
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. CSL Limited
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Merck & Co., Inc.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Pfizer, Inc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. anti-venom market, by species, 2018 - 2030 (USD Million)
• Table 3 U.S. anti-venom market, by snake 2018 - 2030 (USD Million)
• Table 4 U.S. anti-venom market, by type 2018 - 2030 (USD Million)
• Table 5 U.S. anti-venom market, by mode of action 2018 - 2030 (USD Million)
• Table 6 U.S. anti-venom market, by end use 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. anti-venom market: market outlook
• Fig. 10 U.S. anti-venom competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 U.S. anti-venom market driver impact
• Fig. 16 U.S. anti-venom market restraint impact
• Fig. 17 U.S. anti-venom market strategic initiatives analysis
• Fig. 18 U.S. anti-venom market: Species movement analysis
• Fig. 19 U.S. anti-venom market: Species outlook and key takeaways
• Fig. 20 Snake market estimates and forecasts, 2018 - 2030
• Fig. 21 Common cobra market estimates and forecasts, 2018 - 2030
• Fig. 22 Common krait market estimates and forecasts, 2018 - 2030
• Fig. 23 Russell viper market estimates and forecasts, 2018 - 2030
• Fig. 24 Others market estimates and forecasts, 2018 - 2030
• Fig. 25 Scorpion market estimates and forecasts, 2018 - 2030
• Fig. 26 Spider market estimates and forecasts, 2018 - 2030
• Fig. 27 Other market estimates and forecasts, 2018 - 2030
• Fig. 28 U.S. anti-venom market: Type movement analysis
• Fig. 29 U.S. anti-venom market: Type outlook and key takeaways
• Fig. 30 Polyvalent market estimates and forecasts, 2018 - 2030
• Fig. 31 Monovalent market estimates and forecasts, 2018 - 2030
• Fig. 32 U.S. anti-venom market: Mode of Action movement analysis
• Fig. 33 U.S. anti-venom market: Mode of Action outlook and key takeaways
• Fig. 34 Cytotoxic market estimates and forecasts, 2018 - 2030
• Fig. 35 Neurotoxic market estimates and forecasts, 2018 - 2030
• Fig. 36 Hemotoxic market estimates and forecasts, 2018 - 2030
• Fig. 37 Cardiotoxic market estimates and forecasts, 2018 - 2030
• Fig. 38 Myotoxic market estimates and forecasts, 2018 - 2030
• Fig. 39 Others market estimates and forecasts, 2018 - 2030
• Fig. 40 U.S. anti-venom market: End Use movement analysis
• Fig. 41 U.S. anti-venom market: End Use outlook and key takeaways
• Fig. 42 Hospitals market estimates and forecasts, 2018 - 2030
• Fig. 43 Clinics market estimates and forecasts, 2018 - 2030
• Fig. 44 Ambulatory surgical centers market estimates and forecasts, 2018 - 2030